Abstract：
Aim: To understand the real-world use of abemaciclib in Japanese patients with early breast cancer (EBC). Methods: This retrospective observational study was conducted using a Japanese administrative claims database in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative EBC who received abemaciclib adjuvant therapy from December 2021-March 2023. Patient characteristics and treatment patterns were summarized. Results: Among 374 patients, 38.2, 51.6 and 63.4% patients received neoadjuvant chemotherapy, adjuvant chemotherapy and radiotherapy, respectively; 13.1% were chemotherapy naive. Tamoxifen (37.7%), letrozole (35.6%), anastrozole (24.3%) were the commonly prescribed concomitant adjuvant endocrine therapies. Abemaciclib dose reductions were observed in 42.0% patients. Conclusion: Use of abemaciclib for treatment of high-risk EBC was described, which could help inform patient selection and treatment patterns.
Abemaciclib (150 mg twice daily) is prescribed with hormonal therapy for the treatment of early breast cancer (EBC) with high risk of recurrence. We used a big database from Japan that has anonymized information about 44 million patients from 480 hospitals. We aim to describe the characteristics of patients with EBC who receive abemaciclib and their treatment patterns in Japan.We included 374 patients with EBC who had breast cancer surgery and were prescribed abemaciclib with hormonal therapy between December 2021 and March 2023. The median age of patients is 54 years, almost all (99.2%) are female. The most commonly prescribed hormonal therapy with abemaciclib is tamoxifen (37.7%), letrozole (35.6%) and anastrozole (24.3%).Of the 374 patients who were prescribed abemaciclib, 38.2% patients received chemotherapy before surgery, 51.6% received chemotherapy after surgery and 63.4% received radiation therapy after surgery; whereas, 13.1% received no perioperative chemotherapy before abemaciclib therapy. Around 42% of patients reduced their dose from starting dose of abemaciclib. Higher proportion of older patients and patients with low body weight, had dose reduction. Majority of the patients are prescribed either an antidiarrheal agent or probiotic within a day of starting abemaciclib.This is the first study describing patient characteristics and treatment patterns of Japanese patients who are prescribed abemaciclib in the clinical practice. The results will help understand who can benefit from abemaciclib, and to choose the most appropriate patients to receive abemaciclib for the treatment of EBC.
Abemaciclib (150 mg twice daily) is prescribed with hormonal therapy for the treatment of early breast cancer (EBC) with high risk of recurrence. We used a big database from Japan that has anonymized information about 44 million patients from 480 hospitals. We aim to describe the characteristics of patients with EBC who receive abemaciclib and their treatment patterns in Japan.We included 374 patients with EBC who had breast cancer surgery and were prescribed abemaciclib with hormonal therapy between December 2021 and March 2023. The median age of patients is 54 years, almost all (99.2%) are female. The most commonly prescribed hormonal therapy with abemaciclib is tamoxifen (37.7%), letrozole (35.6%) and anastrozole (24.3%).Of the 374 patients who were prescribed abemaciclib, 38.2% patients received chemotherapy before surgery, 51.6% received chemotherapy after surgery and 63.4% received radiation therapy after surgery; whereas, 13.1% received no perioperative chemotherapy before abemaciclib therapy. Around 42% of patients reduced their dose from starting dose of abemaciclib. Higher proportion of older patients and patients with low body weight, had dose reduction. Majority of the patients are prescribed either an antidiarrheal agent or probiotic within a day of starting abemaciclib.This is the first study describing patient characteristics and treatment patterns of Japanese patients who are prescribed abemaciclib in the clinical practice. The results will help understand who can benefit from abemaciclib, and to choose the most appropriate patients to receive abemaciclib for the treatment of EBC.
摘要：
目的：了解日本早期乳腺癌（EBC）患者使用abemaciclib的实际情况。方法：这项回顾性观察研究是使用日本行政索赔数据库对激素受体阳性患者进行的，从2021年12月至2023年3月接受abemaciclib辅助治疗的人表皮生长因子受体2阴性EBC.总结了患者特征和治疗模式。结果：在374例患者中，38.2、51.6和63.4％的患者接受新辅助化疗，辅助化疗和放疗，分别为13.1%的患者为未接受化疗。他莫昔芬（37.7%），来曲唑（35.6%），阿那曲唑(24.3%)是常用的辅助内分泌治疗。在42.0％的患者中观察到Abemaciclib剂量减少。结论：描述了使用abemaciclib治疗高危EBC，这可以帮助告知患者选择和治疗模式。
Abemaciclib（150毫克，每日两次）与激素疗法一起用于治疗复发风险高的早期乳腺癌（EBC）。我们使用了一个来自日本的大型数据库，该数据库匿名了来自480家医院的4400万患者的信息。我们旨在描述在日本接受abemaciclib的EBC患者的特征及其治疗模式。我们纳入了374例EBC患者，他们在2021年12月至2023年3月期间接受了乳腺癌手术，并接受了abemaciclib和激素治疗。患者的平均年龄为54岁，几乎所有（99.2%）都是女性。使用abemaciclib最常用的激素治疗是他莫昔芬（37.7％），来曲唑（35.6%）和阿那曲唑（24.3%）。在374名服用abemaciclib的患者中，38.2%的患者在手术前接受化疗,51.6%的人术后接受化疗，63.4%的人术后接受放疗；13.1%的患者在接受abemaciclib治疗前未接受围手术期化疗。大约42％的患者从abemaciclib的起始剂量减少了剂量。老年患者和低体重患者比例较高，剂量减少了。大多数患者在开始使用abemaciclib的一天内服用了止泻药或益生菌。这是第一项描述在临床实践中使用abemaciclib的日本患者的患者特征和治疗模式的研究。结果将有助于了解谁可以从abemaciclib中受益，并选择最合适的患者接受abemaciclib治疗EBC。
Abemaciclib（150毫克，每日两次）与激素疗法一起用于治疗复发风险高的早期乳腺癌（EBC）。我们使用了一个来自日本的大型数据库，该数据库匿名了来自480家医院的4400万患者的信息。我们旨在描述在日本接受abemaciclib的EBC患者的特征及其治疗模式。我们纳入了374例EBC患者，他们在2021年12月至2023年3月期间接受了乳腺癌手术，并接受了abemaciclib和激素治疗。患者的平均年龄为54岁，几乎所有（99.2%）都是女性。使用abemaciclib最常用的激素治疗是他莫昔芬（37.7％），来曲唑（35.6%）和阿那曲唑（24.3%）。在374名服用abemaciclib的患者中，38.2%的患者在手术前接受化疗,51.6%的人术后接受化疗，63.4%的人术后接受放疗；13.1%的患者在接受abemaciclib治疗前未接受围手术期化疗。大约42％的患者从abemaciclib的起始剂量减少了剂量。老年患者和低体重患者比例较高，剂量减少了。大多数患者在开始使用abemaciclib的一天内服用了止泻药或益生菌。这是第一项描述在临床实践中使用abemaciclib的日本患者的患者特征和治疗模式的研究。结果将有助于了解谁可以从abemaciclib中受益，并选择最合适的患者接受abemaciclib治疗EBC。
